Comorbidity and quality of life in obesity-a comparative study with the general population in Gothenburg, Sweden

PLoS One. 2022 Oct 4;17(10):e0273553. doi: 10.1371/journal.pone.0273553. eCollection 2022.

Abstract

Context: Obesity is considered to have a detrimental impact on health-related quality of life (HRQoL).

Objective: To compare HRQoL in a well-defined group of people with obesity with a population-based control group from the general public.

Design: Observational cross-sectional cohort study with a reference population.

Setting: The Regional Obesity Center at the Department of Medicine at Sahlgrenska University Hospital, Gothenburg, Sweden.

Participants: People with obesity (n = 1122) eligible for surgical and non-surgical obesity treatment in routine care were included consecutively between 2015 and 2017 into the BASUN study. Men and women from the WHO-MONICA-GOT project were used as a reference population (n = 414).

Main outcome measures: HRQoL was measured with the RAND-36/Short Form-36 questionnaire (SF-36) and a Visual Analogue Scale (VAS) for self-related health (SRH). Prescription drugs for hypertension, diabetes mellitus, depression, and anxiety were taken as a proxy for these conditions.

Results: People with obesity rated their overall HRQoL lower than the reference population according to the SRH-VAS. Lower scores were reported on physical and social functioning, vitality, general and mental health after adjustment for age and use of prescription drugs (considered a proxy for burden of disease, or comorbidities) using the RAND-36/SF-36 questionnaire. Use of some psychopharmacological agents was more common in patients with obesity.

Conclusion: People with obesity seeking help with weight reduction are more likely to have lower physical and mental self-reported HRQoL than the general population.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Comorbidity
  • Cross-Sectional Studies
  • Female
  • Humans
  • Male
  • Obesity* / epidemiology
  • Quality of Life*
  • Surveys and Questionnaires
  • Sweden / epidemiology

Grants and funding

Kerstin Landin-Wilhelmsen - The Swedish State (ALFGBG-725291). https://www.alfvastragotaland.se/ Björn Eliasson - Novo Nordisk Foundation (NNF16OC0020936). https://novonordiskfonden.dk/en/ Björn Eliasson - Västra Götalandsregionen (HS 2018-00061). https://www.vgregion.se/ NO - The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.